BD750, a benzothiazole derivative, inhibits T cell proliferation by affecting the JAK3/STAT5 signalling pathway

British Journal of Pharmacology

Volumn 168, Issue 3, 2013, Pages 632-643

  Liu, Y ^a   Yang, T ^a   Li, H ^b   Li, M H ^a   Liu, J ^a   Wang, Y T ^a   Yang, S X ^a   Zheng, J ^a   Luo, X Y ^a   Lai, Y ^a   Yang, P ^a   Li, L M ^a   Zou, Q ^a  

^a CHENGDU MEDICAL COLLEGE   (China)

^b CHENGDU MILITARY GENERAL HOSPITAL   (China)

Author keywords

benzothiazol derivate; immunosuppressants; JAK3 STAT5 signal pathway; T cell proliferation

Indexed keywords

2 (2 BENZOTHIAZOLEYL) 4,5,6,7 TETRAHYDRO 2H INDAZOL 3 OL; BD 750; BENZOTHIAZOLE DERIVATIVE; CD69 ANTIGEN; CYCLOSPORIN A; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; JANUS KINASE 3; PROTEIN KINASE B; S6 KINASE; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG STRUCTURE; DRUG SYNTHESIS; EAR EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

ALLERGENS; ANIMALS; BENZOTHIAZOLES; CELL CYCLE; CELL PROLIFERATION; DINITROFLUOROBENZENE; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOSUPPRESSIVE AGENTS; INDAZOLES; INTERLEUKIN-2; JANUS KINASE 3; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTES;

EID: 84872408477     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02172.x     Document Type: Article

References (47)

1. Abdel-Aziza HA, Abdel-Wahab BF, Badria FA, (2010). Stereoselective synthesis and antiviral activity of (1E,2Z,3E)-1-(piperidin-1-yl)-1- (arylhydrazono)-2-[(benzoyl/benzothiazol-2 -oyl)hydrazono]-4-(aryl(1))but-3- enes. Arch Pharm (Weinheim) 343: 152-159.
2. Abraham RT, Wiederrecht GJ, (1996). Immunopharmacology of rapamycin. Annu Rev Immunol 14: 483-510.
3. Ajchenbaum F, Ando K, DeCaprio JA, Griffin JD, (1993). Independent regulation of human d-type cyclin gene expression during G1 phase in primary human T lymphocytes. J Biol Chem 268: 4113-4119.
4. Amirthaganesan S, Aridoss G, Park KS, Lim KT, Jeong YT, (2010). Synthesis, spectral and antimicrobial studies of some N (2)-substituted tetrahydroindazoles. Bull Korean Chem Soc 31: 1135-1142.
5. Aversa G, Chang CC, Carballido JM, Cocks BG, de Vries JE, (1997). Engagement of the signaling lymphocytic activation molecule (SLAM) on activated T cells results in IL-2-independent, cyclosporin A-sensitive T cell proliferation and IFN-gamma production. J Immunol 158: 4036-4044.
6. Bartok B, Firestein GS, (2010). Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunological reviews 233: 233-255.
7. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, et al. (1994). A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369: 756-758.
8. Chakraborty M, Jin KJ, Glover SA, Novak M, (2010). Characterization of the 4-(benzothiazol-2-yl)phenylnitrenium ion from a putative metabolite of a model antitumor drug. J Org Chem 75: 5296-5304.
9. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, et al. (2003). Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302: 875-878.
10. Deuse T, Velotta JB, Hoyt G, Govaert JA, Taylor V, Masuda E, et al. (2008). Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection. Transplantation 85: 885-892.
11. Flanagan ME, Blumenkopf TA, Brissette WH, Brown MF, Casavant JM, Shang-Poa C, et al. (2010). Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 53: 8468-8484.
12. Franklin RA, Tordai A, Patel H, Gardner AM, Johnson GL, Gelfand EW, (1994). Ligation of the T cell receptor complex results in activation of the Ras/Raf-1/MEK/MAPK cascade in human T lymphocytes. J Clin Invest 93: 2134-2140.
13. Ghoreschi K, Laurence A, O'Shea JJ, (2009). Janus kinases in immune cell signaling. Immunol Rev 228: 273-287.
14. Gummert JF, Ikonen T, Morris RE, (1999). Newer immunosuppressive drugs: a review. J Am Soc Nephrol 10: 1366-1380.
15. van Gurp EA, Schoordijk-Verschoor W, Klepper M, Korevaar SS, Chan G, Weimar W, et al. (2009). The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients. Transplantation 87: 79-86.
16. Halloran PF, (2004). Immunosuppressive drugs for kidney transplantation. N Engl J Med 351: 2715-2729.
17. Hulin A, (2008). Today in molecular mechanisms of immunosuppressive drugs actions: roles of pharmacist. Ann Pharm Fr 66: 102-114.
18. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
19. Kobayashi K, Kaneda K, Kasama T, (2001). Immunopathogenesis of delayed-type hypersensitivity. Microsc Res Tech 53: 241-245.
20. Liu J, Farmer JD, Jr, Lane WS, Friedman J, Weissman I, Schreiber SL, (1991). Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66: 807-815.
21. Lucas JJ, Szepesi A, Modiano JF, Domenico J, Gelfand EW, (1995). Regulation of synthesis and activity of the PLSTIRE protein (cyclin-dependent kinase 6 (cdk6)), a major cyclin d-associated cdk4 homologue in normal human T lymphocytes. J Immunol 154: 6275-6284.
22. Marcen R, (2009). Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 69: 2227-2243.
23. Mase T, Arima H, Tomioka K, Yamada T, Murase K, (1986). Imidazo[2,1-b]benzothiazoles. 2. New immunosuppressive agents. J Med Chem 29: 386-394.
24. Mase T, Arima H, Tomioka K, Yamada T, Murase K, (1988). Imidazo [2, 1-b] benzothiazoles 3: syntheses and immunosuppressive activities of 2-(m-acyloxyphenyl) imidazo [2, 1-b] benzothiazoles. Eur J Med Chem 23: 335-339.
25. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reportingexperiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
26. Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D, et al. (1999). Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 10: 249-259.
27. Noss EH, Brenner MB, (2008). The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunological reviews 223: 252-270.
28. Patel AM, Lupash D, Chew D, Levesque MC, Moreland LW, (2011). JAK inhibition in rheumatoid arthritis. Curr Rheumatol Rep 13: 379-380.
29. Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O'Shea JJ, (2005). Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 203: 127-142.
30. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ, (2008). Therapeutic targeting of Janus kinases. Immunol Rev 223: 132-142.
31. Ponticelli C, (2011). Present and future of immunosuppressive therapy in kidney transplantation. Transplant Proc 43: 2439-2440.
32. Segoloni GP, Quaglia M, (2006). New immunosuppressive drugs for prevention and treatment of rejection in renal transplant. J Nephrol 19: 578-586.
33. Senda M, DeLustro B, Eugui E, Natsumeda Y, (1995). Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation 60: 1143-1148.
34. Shi L, Wang L, Wang Z, Zhu HL, Song Q, (2012). Synthesis of novel cinnamanilides as potential immunosuppressive agents. Eur J Med Chem 47: 585-593.
35. el-Shorbagi AN, Sakai S, el-Gendy MA, Omar N, Farag HH, (1989). Imidazo[2,1-b]benzothiazoles. II. Synthesis and antiinflammatory activity of some imidazo[2,1-b]benzothiazoles. Chem Pharm Bull (Tokyo) 37: 2971-2975.
36. Siddiqui N, Rana A, Khan SA, Haque SE, Arshad MF, Ahmed S, et al. (2009). Synthesis and preliminary screening of benzothiazol-2-yl thiadiazole derivatives for anticonvulsant activity. Acta Pharm 59: 441-451.
37. Sigal NH, Dumont FJ, (1992). Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 10: 519-560.
38. Stallone G, Infante B, Gesualdo L, (2005). Immunosuppressive drugs and renal transplantation. G Ital Nefrol 22 (Suppl. 33): S76-S79.
39. Stucker F, Ackermann D, (2011). Immunosuppressive drugs-how they work, their side effects and interactions. Ther Umsch 68: 679-686.
40. Takenaka H, Maruo S, Yamamoto N, Wysocka M, Ono S, Kobayashi M, et al. (1997). Regulation of T cell-dependent and -independent IL-12 production by the three Th2-type cytokines IL-10, IL-6, and IL-4. J Leukoc Biol 61: 80-87.
41. Van Zandt MC, Doan B, Sawicki DR, Sredy J, Podjarny AD, (2009). Discovery of [3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]ac etic acids as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. Bioorg Med Chem Lett 19: 2006-2008.
42. Vella AT, Dow S, Potter TA, Kappler J, Marrack P, (1998). Cytokine-induced survival of activated T cells in vitro and in vivo. Proc Natl Acad Sci U S A 95: 3810-3815.
43. Velotta JB, Deuse T, Haddad M, Masuda E, Park G, Carroll D, et al. (2009). A novel JAK3 inhibitor, R348, attenuates chronic airway allograft rejection. Transplantation 87: 653-659.
44. Wang D, Matsumoto R, You Y, Che T, Lin XY, Gaffen SL, et al. (2004). CD3/CD28 costimulation-induced NF-kappaB activation is mediated by recruitment of protein kinase C-theta, Bcl10, and IkappaB kinase beta to the immunological synapse through CARMA1. Mol Cell Biol 24: 164-171.
45. Wang J, Wang F, Xiao Z, Sheng G, Li Y, Wang Y, (2012). Molecular simulation of a series of benzothiazole PI3Kalpha inhibitors: probing the relationship between structural features, anti-tumor potency and selectivity. J Mol Model 18: 2943-2958.
46. Xie C, Patel R, Wu T, Zhu J, Henry T, Bhaskarabhatla M, et al. (2007). PI3K/AKT/mTOR hypersignaling in autoimmune lymphoproliferative disease engendered by the epistatic interplay of Sle1b and FASlpr. Int Immunol 19: 509-522.
47. Xiong Z, Ma A, Chen H, (2010). JAK3 inhibitors in organ transplantation and autoimmune disease. Recent Pat Inflamm Allergy Drug Discov 4: 75-81.